CARSGEN-B (02171): Research Updates on CT0596 to be Presented at 2025 ASH Annual Meeting

Stock News

Oct 06

CARSGEN-B (02171) announced that it will present clinical data for CT0596, a BCMA-targeting allogeneic CAR-T cell candidate, at the 67th American Society of Hematology (ASH) Annual Meeting. The abstract and additional information will be released after November 3, 2025, Eastern Time.

CT0596 is a universal CAR-T cell therapy targeting BCMA, developed based on CARSGEN's proprietary THANK-u Plus™ platform, and is currently undergoing investigator-initiated clinical trials in relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). CT0596 has demonstrated preliminary favorable safety profile and encouraging efficacy signals, with CAR-T cell expansion observed across all predetermined dose groups.

Beyond R/R MM, the company also plans to further explore CT0596 in other plasma cell malignancies as well as autoreactive plasma cell-driven autoimmune diseases. The company anticipates submitting an IND application for this product candidate in the second half of 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1119933344"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119933344\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119933344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119933344","market":"other","top_or_hot":-1,"title":"CARSGEN-B (02171): Research Updates on CT0596 to be Presented at 2025 ASH Annual Meeting","media":"Stock News","content":"<p>CARSGEN-B (02171) announced that it will present clinical data for CT0596, a BCMA-targeting allogeneic CAR-T cell candidate, at the 67th American Society of Hematology (ASH) Annual Meeting. The abstract and additional information will be released after November 3, 2025, Eastern Time.</p>\n<p>CT0596 is a universal CAR-T cell therapy targeting BCMA, developed based on CARSGEN's proprietary THANK-u Plus™ platform, and is currently undergoing investigator-initiated clinical trials in relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). CT0596 has demonstrated preliminary favorable safety profile and encouraging efficacy signals, with CAR-T cell expansion observed across all predetermined dose groups.</p>\n<p>Beyond R/R MM, the company also plans to further explore CT0596 in other plasma cell malignancies as well as autoreactive plasma cell-driven autoimmune diseases. The company anticipates submitting an IND application for this product candidate in the second half of 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B (02171): Research Updates on CT0596 to be Presented at 2025 ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B (02171): Research Updates on CT0596 to be Presented at 2025 ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-06 08:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) announced that it will present clinical data for CT0596, a BCMA-targeting allogeneic CAR-T cell candidate, at the 67th American Society of Hematology (ASH) Annual Meeting. The abstract and additional information will be released after November 3, 2025, Eastern Time.</p>\n<p>CT0596 is a universal CAR-T cell therapy targeting BCMA, developed based on CARSGEN's proprietary THANK-u Plus™ platform, and is currently undergoing investigator-initiated clinical trials in relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). CT0596 has demonstrated preliminary favorable safety profile and encouraging efficacy signals, with CAR-T cell expansion observed across all predetermined dose groups.</p>\n<p>Beyond R/R MM, the company also plans to further explore CT0596 in other plasma cell malignancies as well as autoreactive plasma cell-driven autoimmune diseases. The company anticipates submitting an IND application for this product candidate in the second half of 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1585","symbol_name":"昨日强势股","start_time":0,"source_url":"","article_id":"1119933344","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119933344","pubTimestamp":1759709209,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) announced that it will present clinical data for CT0596, a BCMA-targeting allogeneic CAR-T cell candidate, at the 67th American Society of Hematology (ASH) Annual Meeting. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1585":"昨日强势股","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","02171":"科济药业-B","ASH":"Ashland","BK1587":"次新股","BK4109":"特种化学制品","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"科济康-B(02171)：CT0596的研究更新将在2025年ASH年会上发表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1,"ASH":1},"content_text":"CARSGEN-B (02171) announced that it will present clinical data for CT0596, a BCMA-targeting allogeneic CAR-T cell candidate, at the 67th American Society of Hematology (ASH) Annual Meeting. The abstract and additional information will be released after November 3, 2025, Eastern Time.\nCT0596 is a universal CAR-T cell therapy targeting BCMA, developed based on CARSGEN's proprietary THANK-u Plus™ platform, and is currently undergoing investigator-initiated clinical trials in relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). CT0596 has demonstrated preliminary favorable safety profile and encouraging efficacy signals, with CAR-T cell expansion observed across all predetermined dose groups.\nBeyond R/R MM, the company also plans to further explore CT0596 in other plasma cell malignancies as well as autoreactive plasma cell-driven autoimmune diseases. The company anticipates submitting an IND application for this product candidate in the second half of 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}